Author: admin

New York, NY – September 01, 2025 – (SeaPRwire) – me88news, a dedicated sports journalism platform, announced its official launch today, designed to provide comprehensive coverage and expert analysis across four key competitive disciplines: Formula 1, E-sports, Badminton, and Martial Arts. Addressing the Information Gap in Sports Media The launch of me88 news responds to the growing demand for specialized sports content that goes beyond surface-level reporting. Unlike traditional sports platforms that prioritize click-driven headlines, me88 news focuses on delivering substantive analysis, technical breakdowns, and exclusive behind-the-scenes content that enhances readers’ understanding of competitive sports. “The sports media landscape is saturated with recycled content and sensational headlines,” said Owen Parker at me88 news. “Our platform represents a commitment to journalism that respects both the intelligence of our audience and the complexity of modern competitive sports.” Comprehensive Multi-Sport Coverage me88 news provides specialized reporting across four distinct sporting categories: Formula 1: Technical analysis covering paddock politics, pit lane strategies, and the engineering innovations that define modern motorsport E-sports: Tournament coverage, player profiles, and analysis of the rapidly evolving digital athletics landscape Badminton: In-depth coverage of one of the world’s most physically demanding racket sports, featuring tactical analysis and athlete profiles Martial Arts: Comprehensive reporting spanning traditional disciplines to modern competitive fighting, honoring both heritage and contemporary innovation Real-Time Global Coverage The platform operates with around-the-clock reporting capabilities, ensuring readers receive timely updates regardless of global time zones. Features include live event coverage, instant post-competition analysis, and multimedia content including highlight reels and exclusive interviews. Beyond breaking news, me88 news offers editorial content designed to foster informed discussion within the sports community, including opinion pieces, feature stories, and long-form investigations into the human stories behind athletic achievement. Industry Positioning and Future Outlook me88 news enters a competitive digital sports media market with a differentiated approach focused on quality over quantity. The platform’s launch reflects broader industry trends toward specialized content and expert analysis as audiences increasingly seek authoritative sources for sports information. The company plans to expand coverage areas and enhance multimedia offerings as the platform develops its audience base and establishes its position within the sports media ecosystem. About me88 news me88 news is a sports journalism platform dedicated to providing comprehensive coverage and analysis across multiple competitive disciplines. Through strategic partnerships and expert-driven content, me88 news serves sports enthusiasts seeking in-depth analysis that enhances their understanding and appreciation of competitive athletics. Media Contact Company: me88 news Contact: Media Team Email: hello@me88news.com Website: https://me88news.com/

連續 8 年年化回報超 20%，Duoer Capital 再次升級戰略，以「安全+合規」為投資人保駕護航 【2025年·新加坡】在全球市場波動與不確定性加劇的背景下，投資者愈發關注 穩健收益與資金安全。Duoer Capital Management Co.,Ltd 今日宣布，將全面啟動新基金計劃，以 AI + Web3 為核心驅動，為投資人開啟數字經濟新藍海。 連續八年穩健表現 Duoer Capital 的旗艦量化基金已連續八年實現 20%+ 年化回報，夏普比率保持在行業領先的 2.0+ 水平，最大回撤始終低於 15%。這一紀錄展現了公司在風險控制與超額收益方面的專業實力。 雙軌並行：傳統+數字資產 新基金將採取「雙軌策略」： 傳統市場：股票、期貨等繼續由 AI 增強策略驅動； 數字市場：重點布局加密資產、DeFi 與 NFT，捕捉下一代數字經濟紅利。 安全合規：投資人的信心保障 Duoer Capital 特別強調合規與安全： 全球監管許可：已獲得 SEC、FCA、SFC 認可，並持有 美國 MSB 金融牌照，合法開展數字資產與跨境支付業務； 風險管理體系：LVaR、鏈上風險評級、熔斷機制全方位保障； 安全審計：與國際頂尖安全機構合作，確保 DeFi 協議與智能合約的穩健性。 即將推出：AI 驅動數字資產基金 2025 年，公司將推出首隻 AI 驅動數字資產基金，由 AI 多因子模型自動化管理投組，並在鏈上進行透明執行，確保投資人全程可追溯、可驗證。 結語 對投資人而言，Duoer Capital 不僅是一家基金公司，更是一個 可信賴的合規投資入口。在 AI 與 Web3 的賦能下，公司將為投資人帶來 穩健回報、合規保障、前瞻機遇。

New York, NY – August 28, 2025 – (SeaPRwire) – As part of its launch, Poolbetx (https://poolbetx.com) proudly introduces its Token (PBX), a stable crypto coin designed as a digital igaming chip for the Poolbetx ecosystem. Built on TON Blockchain: PBX runs on the highly scalable TON blockchain, ensuring speed, low fees, and reliability. Global Accessibility: PBX can be accessed and traded across all major DEX pools including DeDust.io and Ston.fi. Wallet Integration: Customers can easily buy, exchange, or cash out PBX tokens directly through Telegram Wallet and TON Hub Wallet, available on the Apple App Store and Google Play Store. Borderless & Jurisdiction-Free: PBX enables seamless global usage, allowing Poolbetx players to withdraw, play, and transact without jurisdictional restrictions – a world-first innovation in crypto igaming platforms. “PBX is more than a token – it’s a bridge between our global customers and the Poolbetx ecosystem,” said a Poolbetx spokesperson. “By making PBX accessible on everyday apps like Telegram and Tonhub, we’re ensuring anyone, anywhere, can join Poolbetx with ease.” With PBX, Poolbetx not only provides premium i- games but also a financial infrastructure that redefines global access to entertainment. Related Links Telegram: https://t.me/poolbetx PBX on DeDust: https://dedust.io/ PBX on Stonfi: https://ston.fi/ Media contact Brand: Poolbetx Contact: media team Email: support@poolbetx.com Website: https://poolbetx.com

New York, NY – August 27, 2025 – (SeaPRwire) – T-RIZE Group, a global fintech firm offering institutional-grade tokenization infrastructure, is launching Vision 60 by Ste-Rose, a $24.2 million, 60-unit energy-efficient residential development in Laval, Québec. This project is part of a 500+ unit new construction deal with T-RIZE Group, valued at $200 million. Tokenized by T-RIZE, the offering is being launched through a strategic collaboration with Republic, one of the world’s leading regulated investment platforms with over 3 million users, $3 billion in deployed capital, and more than 2,500 ventures backed. Accredited investors will be able to participate using both fiat and cryptocurrency. Pipeline Execution in Motion Vision 60 by Ste-Rose follows Vision 87 by Champfleury, an 87-unit, $23 million tokenized offering that forms part of a separate $300 million, 956-unit residential development. Together, these offerings reflect the ongoing execution of T-RIZE’s multi-billion-dollar pipeline, applying a scalable, compliant framework for bringing real-world assets onchain. T-RIZE leads tokenization, including asset digitization, legal structuring, and smart contract deployment. Republic’s affiliate broker-dealer, OpenDeal Broker LLC , Member FINRA & SiPC, oversees investor onboarding and distribution under Regulation D. Token-Powered Infrastructure Vision 60 will be deployed on an EVM-compatible blockchain such as Base or Avalanche, two leading infrastructures supporting institutional adoption of real-world assets. Base, incubated by Coinbase, enables low-cost execution, robust security, and seamless integration with Ethereum and capital markets ecosystems, offering a strong foundation for tokenized financial products. Avalanche delivers high-performance infrastructure with flexible tooling, supporting regulatory alignment and scalable deployment of institutional tokenization use cases. The $RIZE utility token anchors the T-RIZE ecosystem. It is used to access and pay for tokenization services—including onboarding, structuring, and listing—while also unlocking vetted investment opportunities, enabling decentralized governance, and supporting ecosystem growth. With 30% of supply allocated to governance and incentives, $RIZE is listed on tier-1 venues like Kraken and Revolut. Built with Institutional-Grade Standards Vision 60 is supported by a network of third-party experts and institutions: ● Ekitas – Legal and tax structuring ● CBRE – Independent project appraisal ● BDO – Return and cash flow projections ● Intact Insurance – Performance bond underwriting ● MA2D – Lead developer ● Concept Habitation Duo Inc. – Property manager ● Republic – Regulated global investment platform T-RIZE also operates as a validator and RWA issuer on the Canton Network, a privacy-first blockchain used by institutions such as Goldman Sachs, Broadridge, and Cumberland, where over $2 trillion in monthly transactions are settled and more than $4 trillion in digital assets are safeguarded. This positions T-RIZE at the intersection of regulated finance and onchain innovation. “Tokenized real estate is no longer a concept—it’s entering its institutional growth phase,” said Madani Boukalba, CEO of T-RIZE Group. “Vision 60 is a real-world proof point of how scalable, compliant infrastructure unlocks global access to tokenized real estate—setting the stage for broader institutional adoption.” About Republic Headquartered in New York City, Republic is a global financial firm operating a network of retail-focused investment platforms and an enterprise digital advisory arm. With a deep track record of legal and technical innovation, Republic is known for providing access to new asset classes to investors of all types. Backed by Valor Equity Partners, Galaxy Interactive, HOF Capital, AngelList and other leading institutions, Republic boasts a global portfolio of over 2,000 companies and a community of nearly three million members in over 150 countries. More than $3 billion has been deployed through investment platforms, funds, and firms within the Republic family of companies with operations established in the US, the UK, EU, the UAE and South Korea. All broker-dealer related securities activity is conducted by OpenDeal Broker LLC, an affiliate of OpenDeal Inc. a registered broker-dealer, and member of FINRA | SiPC, located at 149 5th Avenue, 10th FL, New York, 10010 please check our background on FINRA’s BrokerCheck and Form CRS here. For additional information, visit https://republic.com/ About T-RIZE Group Founded in 2022, T-RIZE is an institutional tokenization platform onboarding a multi-billion-dollar pipeline of real estate, structured financial products, and AI Energy Offset Reserve Notes. The T-RIZE platform transforms these assets into programmable digital instruments that unlock liquidity, lower capital costs, and enhance underwriting and risk modelling while protecting sensitive data through privacy-preserving AI. At its core, the RIZE token powers tokenization services, connects institutions to vetted investments and AI-driven infrastructure, and supports governance and incentive programs across the ecosystem. For more information, visit www.T-RIZE.io or contact: Press Inquiries: press@T-RIZE.io Head Office: 1155 René-Lévesque West, Suite 2500, Montreal, QC H3B 3X7, Canada Toronto Office: 130 King Street West, Suite 1900, Toronto, ON M5X 1E3, Canada

PALM BEACH, FL – August 25, 2025 – (SeaPRwire) – BlackRidge & Co, an elite global advisory firm, announced that it has established its official headquarters in Palm Beach, Florida, as the region cements its reputation as “Wall Street South.” The move places the firm at the center of one of the fastest-growing financial hubs in the United States, with additional offices in New York, Silicon Valley, London, and Hong Kong. To learn more about BlackRidge & Co, visit www.blackridgeandco.com The BlackRidge & Co leadership team brings a heritage of advising the most prestigious institutions, including Rothschild Asset Management, Deutsche Bank, and ICBC Hong Kong. Beyond advisory services, the firm’s specialty is orchestrating introductions to capital, forging strategic growth partnerships, and working alongside clients to unlock new markets and drive long-term value creation. “At BlackRidge & Co, our mission is to create opportunities that are often inaccessible through traditional channels—pairing extraordinary companies with the investors and capital they need to scale globally,” said Director of Communications, Isaac Meyer. The migration of capital and talent into South Florida has reshaped the financial landscape. Since Ken Griffin’s Citadel relocated from Chicago to Miami in 2022, major institutions including Goldman Sachs, Blackstone, and Peter Thiel’s Founders Fund have followed, creating a powerful concentration of wealth and influence. Palm Beach has emerged as the crown jewel of this movement, now home to more than 300 hedge funds, private equity firms, and financial institutions. A 2025 Forbes analysis reports that at least 68 billionaires maintain strong ties to Palm Beach, underscoring its position as a magnet for global wealth. About BlackRidge & Co BlackRidge & Co is a global advisory firm headquartered in Palm Beach with hubs in New York, Silicon Valley, London, and Hong Kong. The firm specializes in capital introductions, connecting visionary companies with the world’s most influential financiers, investors, and lenders. Through cultivated relationships and decades of experience, BlackRidge helps clients unlock new opportunities, build partnerships, and create sustainable growth. Media contact Brand: BlackRidge & Co Contact: Isaac Meyer, Director of Communications E-mail: im@blackridgeandco.com Website: https://www.blackridgeandco.com

Hunet Plus Co., Ltd. (CEO Hyukjin Cha), a company specializing in next-generation semiconductor and display materials, announced on Aug. 13th that it has secured Pre-Series B investment for entry into the U.S. market from global semiconductor-related companies, including strategic investors from Japan and Taiwan, as well as the Korean financial investor, ANDA Asia Ventures. In particular, this investment – secured at a time when US and Korea’s tariff issues in the semiconductor sector are coming to the forefront – marks a significant milestone, as it has attracted investment from leading investors from Korea, Japan, and Taiwan. The deal is expected to provide strong momentum not only for securing the original technology of ML-EUV® (Molecular Layer Assembled Extreme UltraViolet Technology, Process and Materials – a multilayer molecular film vacuum process-type photoresist for extreme ultraviolet lithography), but also for obtaining international patents to support market entry into the U.S., Japan and global markets. Furthermore, as one of the few Korean start-up companies to successfully attract foreign investment from Japan and Taiwan, Hunet Plus is expected to gain strong traction in expanding its markets while strengthening its global competitiveness. ML-EUV® is a next-generation total solution for EUV (Extreme Ultraviolet) lithography, encompassing vertically stacked molecular structures, manufacturing processes, and materials. Hunet Plus’ ML-EUV® has overcome the limitations of achieving ultra-high resolution (below 10 nm line width) and sub-2 nm line edge roughness (LER), which have been difficult to realize with existing methods such as: Second-generation chemical amplification resists (wet process, Chemical Amplification Resist) Third-generation inorganic nano-cluster-based resists (wet process, Nano Cluster Based Resist) Fourth-generation inorganic dry-process resists (dry process, Inorganic Precursor Resist) Hunet Plus’ ML-EUV® achieves world-class performance of ultra-high resolution below 10 nm and line edge roughness below 2 nm by using organic precursors and inorganic precursors at the molecular level, forming 10–20 nm ultra-thin multi-layered resist films through its proprietary Organic–Inorganic Molecular Layer Deposition Process® – an innovative dry molecular-layer stacking method. Through this strategic investment, Hunet Plus has formally launched commercialization efforts for ML-EUV®. Based on the world’s highest-performing ML-EUV®, the company plans to jointly commercialize ML-EUV® equipment and processes for dry processing with leading global semiconductor equipment manufacturers, while also supplying core organic and inorganic process materials for ML-EUV®-related semiconductor processes in partnership with global materials companies. In doing so, Hunet Plus aims to position itself as a key player in the semiconductor materials, components, and equipment sector. Hyukjin Cha, CEO of Hunet Plus, stated: “In the global semiconductor market, national borders no longer matter. In the near future, technologies and products like our ML-EUV® – innovative and market-leading – will be the basis for global companies to collaborate and build ecosystems that dominate the market and ensure sustainability. We anticipate additional USD 10 Million follow-on investments from our existing shareholders as well as other global companies, including in the U.S., and will work with local clients to build unique and sustainable ecosystem.” Haesun Kim, Senior Executive Director of HunetPlus, who played a pivotal role in leading the successful domestic and overseas fundraising, drew on more than 25 years of professional experience in international finance and foreign capital attraction, commented: “Although the past two years have been a very challenging period for Hunet Plus – requiring not only navigating detailed and rigorous due diligence imposed by top-tier international investors but also had to lead strategic negotiations – it has been deeply rewarding. In particular, despite a difficult investment climate as well as attracting interest from potential investors to one of the top level industries in the world, this has become a meaningful success story made possible by the organic cooperation with HunetPlus executives.” Cho Namhoon, CEO of K-Ground Ventures, an existing investor and the operator of Scale-Up TIPS who provided behind-the-scenes support for this investment, said: “Even in Korea’s challenging environment for bold investments in original technology, we had a strong belief in Hunet Plus’ global-standard R&D capabilities. Through the Hongneung Advanced Science & Technology Commercialization Fund, we took the bold step of making an early-stage investment, followed by support for subsequent fundraising, reinvestment through the Innovation IP Fund, and additional backing via Scale-Up TIPS. This long-term investment strategy has brought significant results. In particular, the attracting investment from renowned global investors is expected to support U.S. market entry and lead to further follow-on investments, ultimately building a sustainable global supply ecosystem for Korean semiconductor technology through joint Korea–U.S. R&D, production, and marketing.” Meanwhile, on August 6 (local time), U.S. President Donald Trump, at an Apple facility investment announcement event, stated, “We will impose 100% tariffs on every semiconductor imported into the United States.” This announcement has drawn intense attention from semiconductor startups and investors, as semiconductors are the second-largest category of U.S.-bound exports, especially ahead of the upcoming Korea–U.S. summit, where the government’s response will be closely watched. Media contact Brand: Hunet Plus Contact: Hyukjin Cha, CEO Email: support@hunetplus.com Telephone: +82-10-8817-0003 Website: https://en.hunetplus.com

SHENZHEN, CHINA, Aug 19, 2025 – (ACN Newswire via SeaPRwire.com) – On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year. The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth. According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements. “New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value. To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio. Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth. Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option. CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects. Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model. Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential. In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market. Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com Categories: ACN Newswire

2025年8月19日 - (SeaPRwire) - 韓國醫學美容企業 HIGHER Corporation 表示，其全球醫學美容品牌 HILO WAVE 已於7月31日，在首爾江南區 Monaco Space 為來自中華圈的50位網紅成功舉辦了「A New Wave of Beauty with HILO WAVE®」醫美課程。 本次活動邀請了來自台灣、中國、香港等地的50多位網紅參加，旨在介紹 HILO WAVE 的療程，並為他們創造與韓國知名皮膚美容專科醫師直接交流的機會。 在醫美課程中，除了介紹 HILO WAVE 品牌外，專注於抗衰老美容的專科醫師還分別以「A New Wave of Aesthetic」及「A New Wave of Anti-Aging」為題，分享了抗衰老領域的最新趨勢與新發展方向，為與會者帶來了寶貴的資訊交流平台。 特別是在醫師與網紅交流最新皮膚美容趨勢的交流環節中，一位曾接受 HILO WAVE 療程的網紅表示：「我從事金融業，經常有重要會議場合，之前一直為皮膚問題困擾。在朋友推薦下接受了 HILO WAVE 療程，術後完全沒有明顯痕跡，反而感覺皮膚真的變得健康許多。過一段時間後我還打算再次接受 HILO WAVE。」該網紅對療程表現出高度滿意並給予高度評價。 HILO WAVE 是一款基於高分子玻尿酸與低分子玻尿酸相結合的獨家成分 DHC（Dual Hyaluronic Acid Compound）的生物刺激劑，療程中不會產生結節等副作用風險，卻能恢復自然的皮膚豐盈與彈性，這是其最大的差異化優勢。 與傳統膠原蛋白增生療程相比，HILO WAVE 不會出現結節（皮膚表面隆起）等問題，也不需長時間恢復，即使在療程後亦能保持自然狀態，因此被視為「零恢復期」療程而備受關注。 尤其 HILO WAVE 能夠在促進皮膚內膠原蛋白再生的同時，改善整體皮膚狀況，其優異的效果與安全性已獲得韓國多家頂尖抗衰老專科醫院的高度認可，並在海外醫療觀光客群中，以自然且無負擔的療程特性獲得廣泛好評。 據 HIGHER Corporation 表示，HILO WAVE 已在日本與香港正式上市，並即將在印尼正式推出；同時，包含台灣與中國在內的中華圈市場，對該品牌的關注度與諮詢量也在持續上升。 HIGHER Corporation 強調，未來將持續考慮海外醫療市場的特性，加強與醫師、合作夥伴及消費者的交流，並積極展開更多市場推廣活動。

在快速發展的數位貨幣時代，FX8數位貨幣交易所憑藉技術創新與全球化布局，正迅速成為全球投資者信賴的數位資產衍生品交易平台。 全球布局與卓越背景 FX8成立於2018年，由 BitMEX聯合創始人暨前首席技術官 Samuel Reed 創辦，總部位於美國，致力於推動區塊鏈教育、區塊鏈專案孵化，以及加密貨幣衍生品交易。 平台早期參投並孵化了包括 ETH、BNB、ADA、LINK、DOT 在內的數百個頂尖區塊鏈專案。目前，FX8已在全球 200多個國家和地區 為個人用戶及專業機構提供服務，覆蓋北美、歐洲、亞太等主要市場。 FX8 單日交易量超過120億美元，比特幣合約槓桿最高可達 125倍，同時支援多種數位貨幣的高槓桿交易。 我們的願景：技術驅動未來，分潤成就共贏 FX8不僅是一家數位貨幣交易平台，更是全球數位資產生態的基礎設施建設者。 核心團隊成員來自 微軟、Google、Meta 等全球頂尖科技公司，技術骨幹超過800人。FX8計畫投入 2億美元用戶增長基金，以推動全球業務拓展，並以躋身全球前五大交易所為目標。 我們的使命，是以安全、高效、開放的技術與服務，推動行業邁向更公平、更高效、更具活力的新紀元。 創新優勢與生態價值 FX8首創 三大分潤機制，打造透明、可持續增長的交易生態： 模擬倉學習分潤機制 — 新手可在零風險環境中學習交易並獲得獎勵； 實盤跟單分潤機制 — 用戶可跟隨專業交易員策略，共享盈利成果； 手續費返佣機制 — 讓交易本身帶來長期收益。 FX8已獲得 Digichain Capital、CollinStar Capital、Kryptus Capital 三大機構合計 5億美元戰略投資，其中 2億美元 專用於獎勵新用戶。每位新註冊用戶在模擬倉單日最高可獲得 15 USDT 獎勵，幫助投資者在安全環境中快速上手。 為何選擇FX8 安全至上：多層加密與頂級風控保障用戶資產安全； 高流動性：深度市場與高速撮合引擎確保交易順暢； 全球覆蓋：支援200多個國家，多語言、多法幣交易； 社群獎勵：完善的分潤與獎勵機制，助力交易者、領袖與合作夥伴共同成長。 結語 在數位資產高速發展的今天，選擇一個 安全、透明、全球化、創新驅動 的平台至關重要。 憑藉強大的技術實力、卓越的營運能力與開放的生態理念，FX8交易所 為全球投資者提供值得信賴的交易與投資體驗。

HONG KONG - (TimesNewswire) — Leading Chinese AI firm Zhongke WengAI has forged an exclusive strategic partnership with Cherrypicks. The alliance aims to develop and commercialize AI applications in international markets outside mainland China, boosting Hong Kong's AI ecosystem and speeding up the global deployment of Zhongke WengAI's cutting-edge technologies. Cherrypicks will serve as Zhongke WengAI's exclusive commercialization partner outside mainland China. Zhongke WengAI will supply core technologies, enabling joint development and deployment of AI solutions customized for international sectors such as enterprise services, public administration, finance, and healthcare. Dr. Wang Lei, Chairman and Founder of Zhongke WengAI, will join Cherrypicks’ board to help steer overall strategic direction and technical integration across both parties. Dr. Waley Wang, Chairman and Founder of Zhongke WengAI, said: “We attach great importance to our collaboration with Cherrypicks under NetDragon. As an international gateway for innovation with a multilingual environment, Hong Kong is strategically significant for WengAI’s overseas expansion. Cherrypicks’ professional capabilities and local ecosystem network will strongly support the rollout of our AI technologies and products in global markets. We look forward to jointly enabling industry transformation with AI and delivering higher-quality intelligent services for customers worldwide.” Dr. Simon Leung, Vice Chairman of NetDragon, said: “This three-party collaboration exemplifies the convergence of China’s AI ‘go-global’ strategy with Hong Kong’s innovation strengths. As a bridge between the Mainland and international markets, Cherrypicks will leverage synergies to bring leading AI technologies such as the ‘YaYi’ large language model to Hong Kong and overseas, powering smart city development and industry upgrades, and further cementing Hong Kong’s position as an international innovation hub.” Mr. Kenny Chien, CEO of Cherrypicks, said: “We are honored to partner with Zhongke WengAI to bring China’s leading AI technologies and innovations to Hong Kong and the world. By combining our strengths in AI deployment, mobile technologies, and cross-border services, we will develop intelligent products tailored to local and international needs, foster a healthy AI ecosystem in Hong Kong, and help enterprises seize new opportunities in the intelligent era.” As a key AI player with deep technical roots, Zhongke WengAI has developed the YaYi foundation model — a domain-adaptive, multimodal large model with leading capabilities in semantic understanding, reasoning, and decision-making. This model already powers AI solutions for thousands of clients in sectors such as finance, media, healthcare, and scientific research. At the launch event, WengAI introduced its latest research achievement, the YaYi AI-Scientist platform for scientific research, and showcased its international flagship products and technologies. Among them, the social listening product Wisky, powered by the YaYi model and cross-modal retrieval capabilities, enables comprehensive hot-topic trend analysis, cross-modal information retrieval across the web, intelligent report generation, an intelligent radar engine, and intelligent dashboard analytics. Wisky is available via API, on-premises deployment, SaaS, and mobile experiences, allowing users to stay on top of global dynamics anytime, anywhere and helping enterprises sharpen their competitive edge in the era of mobile intelligence. WengAI also unveiled the international version of Yoya, a multimodal (audio/video) content creation tool. Built on 33 leading multimodal capabilities—including video segmentation, image generation, video generation, video cataloging, digital humans/avatars, speech synthesis, and cross-modal retrieval—Yoya serves marketing, branding, and events use cases with agent-driven features such as one-click video creation from raw assets, multilingual video translation, image style transfer, and AI voice cloning. The tool is specially optimized for mobile, enabling users in Hong Kong and worldwide to create high-quality multimedia content on their phones and accelerating the adoption of AI mobile intelligence across creative industries. WengAI further introduced a one-stop Agent development toolkit, offering a zero-code, enterprise-grade platform to address deployment challenges across industries. With this tool, users can rapidly build custom AI agents and leverage mobile technologies for real-time deployment and use, further strengthening Hong Kong’s position as a hub for AI mobile intelligence.Through this partnership, these AI capabilities will be optimised for Hong Kong’s multilingual and cross-border business environment, enabling broader adoption of Mobile AI Agents across scientific, creative, and commercial domains, and accelerating Zhongke WengAI’s international expansion. Through its partnership with Cherrypicks, Zhongke WengAI will combine the strengths of both parties to build cutting-edge AI products for mobile scenarios—for example, integrating Wisky’s social listening with Yoya’s content creation capabilities—to develop mobile intelligent solutions tailored to Hong Kong’s multilingual and cross-border needs, serving a broader international client base and helping enterprises capture new opportunities in the age of intelligent mobility. About Zhongke WengAI Zhongke WengAI is a leading enterprise AI technology service provider founded in 2017. Incubated by the Institute of Automation, Chinese Academy of Sciences, the company focuses on next generation decision intelligence, achieving breakthroughs in core technologies such as multilingual understanding, cross modal semantics, and decision making in complex scenarios. The company has developed DIOS, a proprietary decision intelligence operating system, the X-Data AI data operating system, the YaYi large language model, and the X-Agent platform driving large scale commercial adoption of general AI. The company is a domestic leader in AI for media communications, security, finance, and government affairs, and has served more than 1,000 government and enterprise clients. The company has led or participated in multiple National Key R&D Programs and major national science and technology initiatives. Zhongke WengAI is recognized as a national level “Specialized and Sophisticated Little Giant” enterprise and has been selected to the Forbes China Top 50 AI Companies and the CCID Think Tank (under MIIT) China Top 20 AI Companies. About NetDragon Websoft Holdings Limited NetDragon Websoft Holdings Limited (HKSE: 0777) is a global leader in building internet communities with a long track record of developing and scaling multiple internet and mobile platforms that impact hundreds of millions of users, including previous establishments of China’s first online gaming portal, 17173.com, and China’s most influential smartphone app store platform, 91 Wireless. Established in 1999, NetDragon is one of the most reputable and well-known online game developers in China with a history of successful game titles including Eudemons Online, Heroes Evolved, Conquer Online, and Under Oath. In the past 10 years, NetDragon has also achieved success with its online education business both domestically and globally, and its overseas education business entity, currently a U.S.-listed subsidiary named Mynd.ai, is a global leader in interactive technology and its award-winning interactive displays and software can be found in more than 1 million learning and training spaces across 126 countries. About Cherrypicks Founded in 2000 and headquartered in Hong Kong, Cherrypicks is a subsidiary of NetDragon Websoft Holdings Limited (HKEX: 777). The company focuses on innovative technologies spanning smart cities, augmented reality, artificial intelligence, e‑wallets, and smart location services, and holds a leading position in the Asia‑Pacific region. Cherrypicks’ user experiences and solutions are at the forefront of the industry, and its patented and patent‑pending products have won more than 100 local and international awards representing Hong Kong and China on global stages. The company’s early startup story was featured as a Harvard Business School case study (No. N9‑807‑106). Cherrypicks’ world‑class mobile innovation solutions are trusted by long‑term partners across banking, insurance, F&B, retail, property management, travel, and transportation. For more information, please visit https://www.cherrypicks.com.